![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR...
HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development...
The morning opened up on a high note for this dually-listed company as it announced U.S. Food and Drug Administration (FDA) approval of its Metronidazole Oral Suspension 500mg/5mL ( ATI-1501 ) To...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 14.2857142857 | 0.035 | 0.04 | 0.03 | 19251 | 0.03448055 | CS |
4 | 0 | 0 | 0.04 | 0.045 | 0.03 | 167713 | 0.0368736 | CS |
12 | 0.005 | 14.2857142857 | 0.035 | 0.05 | 0.03 | 117620 | 0.03824983 | CS |
26 | 0.005 | 14.2857142857 | 0.035 | 0.06 | 0.025 | 176915 | 0.03938466 | CS |
52 | -0.015 | -27.2727272727 | 0.055 | 0.08 | 0.025 | 185856 | 0.0444479 | CS |
156 | -0.7 | -94.5945945946 | 0.74 | 1.14 | 0.025 | 196859 | 0.12504194 | CS |
260 | -1.09 | -96.4601769912 | 1.13 | 1.6 | 0.025 | 179158 | 0.28370252 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions